Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.
Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines.
Karyopharm Therapeutics’ selinexor, an oral selective inhibitor of nuclear export (SINE) compound, has succeeded in a phase 2b study by showing a 25.4% overall response rate (ORR) in heavily pretreated patients with refractory multiple myeloma.
Allergan’s migraine drug ubrogepant has succeeded in a phase 3 trial by meeting its co-primary endpoints for a 50mg dose.
Vertex Pharmaceuticals has initiated two phase 3 studies of VX-445, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF).
Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Boehringer Ingelheim and Eli Lilly and Company have entered into an academic collaboration with the University of Oxford to assess the effects of Jardiance (empagliflozin) on heart and kidney disease in adults with chronic kidney disease.
Merck has reported results from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
AstraZeneca said that Tagrisso (osimertinib) in a first line setting has shown significant progression-free survival (PFS) benefit that was preserved through subsequent lines of therapy in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
A new type of cancer vaccine has shown promise in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.